Nutritional support for joint comfort, healthy skin, cardiovascular function and womens health
- Soothing support for joints
- Promotes healthy lipid metabolism
- Supports look and feel of healthy skin
- Promotes premenstrual and menopause comfort
- Cold-pressed oil, 100% pure and solvent free
Patient One Evening Primrose Oil supplies 1000mg of 100% pure, cold-pressed evening primrose oil (EPO), providing 90-110 mg gamma-linolenic acid (GLA) and 630-770 mg of linoleic acid (LA). These important fatty acids play a beneficial role in supporting cellular health and overall good health.
Evening primrose oil has been used for centuries as nutritional support for a broad range of physiological functions, including joint, skin, and cardiovascular health, as well as for reducing symptoms associated with PMS and menopause.
Research reveals versatile health effects of evening primrose oil. Animal studies suggest that EPO may support healthy lipid metabolism and may provide oxidative protection by promoting glutathione reductase and transferase activities. A clinical trial reported that GLA in combination with EPA/DHA significantly promoted healthy cardiovascular function in women.
GLA formed in the body is ultimately metabolized to dihomogammalinolenic acid (DGLA). Several studies suggest that DGLA promotes healthy prostaglandin E1 production and supports healthy cytokine activity, a mechanism that may help to support joint comfort. PGE1 also supports skin and nerve health and may help reduce symptoms associated with PMS.
Regular supplementation with evening primrose oil may be beneficial for people consuming diets high in animal foods and processed vegetable oil and rich in saturated fats, as well as for those with moderate to high consumption of alcohol or a deficiency of zinc, magnesium and Vitamin B6.
References
- Przegl Lek. 2007;64(2):91-9.
- Prostaglandins Leukot Essent Fatty Acids. 2006 Mar;74(3):165-73.
- J J Belch, D Ansell, R Madhok, A ODowd, and R D Sturrock. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study. Ann Rheum Dis. 1988 Feb; 47(2): 96–104.
